ArticleFrontiers in oncology2026
Multiple myeloma associated with secondary plasma cell leukemia, gastric mucosal extramedullary plasmacytic infiltration, and concurrent moderately differentiated papillary adenocarcinoma: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of IgG λ-type multiple myeloma (MM) in a patient who received multiple lines of therapy and achieved repeated remissions. In 2025, the patient experienced a third relapse and had been exposed to proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs), meeting the criteria for triple-refractory disease. At relapse, the patient presented with fatigue and progressive anemia, and peripheral blood smear examination revealed approximately 14% atypical plasma cells, fulfilling the diagnostic criteria for secondary plasma cell leukemia (sPCL). Treatment with the KXD regimen (carfilzomib, cyclophosphamide, dexamethasone) resulted in transient disease stabilization for approximately two months, followed by further progression. During the disease course, the patient developed upper abdominal discomfort. Gastroscopy revealed a focal lesion at the gastric angle, and endoscopic submucosal dissection (ESD) was subsequently performed. Histopathological examination demonstrated a moderately differentiated intramucosal papillary adenocarcinoma of the gastric angle, with tumor infiltration confined to the mucosal layer and negative resection margins. In addition, infiltration of CD138-positive plasma cell-like tumor cells with λ light chain restriction was observed in the gastric lamina propria, consistent with extramedullary disease (EMD). The final diagnosis was relapsed MM complicated by sPCL, gastric mucosal extramedullary plasmacytic infiltration, and synchronous moderately differentiated intramucosal papillary adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.